Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.56 |
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523475 | 1.00 | CXCR2 (0.56) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL4522750 | 0.93 | CXCR2 (0.57) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL4522743 | 0.93 | CXCR2 (0.57) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL4534602 | 0.90 | ELANE (0.53) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL4534596 | 0.90 | ELANE (0.53) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL25548856 | 0.88 | ELANE (0.55) | CXCR2ELANEGPR132MEN1KMT2A | |
| SCHEMBL4521889 | 0.85 | ALDH1A1 (0.51) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL4521881 | 0.85 | ALDH1A1 (0.51) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL4536055 | 0.85 | CXCR2 (0.59) | CXCR2ELANEITGB1ITGA4ITGB3 | |
| SCHEMBL25549035 | 0.85 | ELANE (0.48) | CXCR2ELANEITGB1ITGA4ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227625-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885ELANE 245/4885ITGB1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.